Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced adenocarcinoma of the rectum with or without nodal involvement~  * Stage mrT3-4 and/or mrN1-2, M0~ * Tumors must express wild type K-ras gene~* No distant metastasis~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Able to undergo surgery~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 100 g/L~* Creatinine clearance ≥ 50 mL/min~* AST ≤ 2.5 times upper limit normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must agree to use effective contraception during and for 12 months after completion of study~* No malignancy within the past 5 years with the exception of adequately treated cervical carcinoma in situ or localized nonmelanoma skin cancer~* No psychiatric disorder that would preclude understanding study-related information, giving informed consent, or complying with oral drug intake~* No prior existing conditions that would preclude radiotherapy~* No clinically significant (i.e., active) cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmia even if controlled with medication) or myocardial infarction within the past 12 months~* No lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome~* No serious underlying medical condition that, in the judgement of the investigator, could impair the ability of the patient to participate in the trial (e.g., active autoimmune disease or uncontrolled diabetes)~* No known dihydropyrimidine dehydrogenase deficiency~* No known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs~PRIOR CONCURRENT THERAPY:~* More than 30 days since prior treatment in a clinical trial~* No other concurrent experimental drugs, anticancer therapy, or investigational treatments~* No prior treatment for rectal cancer~* No prior anti-EGFR antibody therapy (e.g., cetuximab) or small-molecule EGFR inhibitors (e.g., erlotinib hydrochloride)~* No concurrent treatment with brivudine, lamivudine, ribavirin, or any other nucleoside analogues~* No organ allografts~* No concurrent drugs contraindicated for use with the trial drugs~* No other concurrent anti-EGFR-targeting agents~* No other concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
- Arm II (Type: ACTIVE_COMPARATOR): Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).